Trial Profile
A 24-Week, Blinded, Randomized, Placebo-Controlled Dose-Ranging Trial of Nasal PYY3-36 for Weight Loss in Healthy Obese Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Peptide YY 3-36 (Primary) ; Sibutramine
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2008 Status changed from in progress to completed.
- 01 Aug 2008 Primary endpoint not met, as reported in a MDRNA media release.
- 08 Jan 2008 Status change from recruiting to in progress, from Nastech Pharmaceutical Company media release.